Budget impact of IV iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France

被引：0
|
作者：
Faller, M. Mathilde [1 ]
Champs, F. O. [1 ]
Moutier, H. [1 ]
Levesque, K. [2 ]
Bourguignon, S. [1 ]
Cohen-Solal, A. [3 ]
机构：
[1] IQVIA, Hlth Econ & Outcome Res, Paris, France
[2] Vifor Pharma, Hlth Econ & Outcome Res, Paris, France
[3] Hosp Lariboisiere, Cardiol, Paris, France
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P608
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [1] BUDGET IMPACT OF IV IRON THERAPY WITH FERRIC CARBOXYMALTOSE IN PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY IN FRANCE
    Bourvignon, S.
    Levesque, K.
    Faller, M.
    Champs, R.
    Gremaud, N.
    Moutier, H.
    Caranhac, G.
    Cohen-Solal, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A607 - A607
  • [2] Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
    Bourguignon, Sandrine
    Faller, Mathilde
    Champs, Francois-Olivier
    Moutier, Helene
    Levesque, Karine
    Caranhac, Gilbert
    Cohen-Solal, Alain
    [J]. ESC HEART FAILURE, 2019, 6 (03): : 559 - 569
  • [3] Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
    Theidel, Ulrike
    Vaatainen, Saku
    Martikainen, Janne
    Soini, Erkki
    Hardt, Thomas
    Doehner, Wolfram
    [J]. ESC HEART FAILURE, 2017, 4 (03): : 274 - 281
  • [4] Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania
    Lorenzovici, Laszlo
    Szekely, Andrea
    Farkas-Raduly, Szabolcs
    Jitaru, Ciprian
    Csanadi, Marcell
    [J]. JOURNAL OF CARDIOVASCULAR EMERGENCIES, 2019, 5 (04): : 131 - 139
  • [5] Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain
    Delgado, Juan F.
    Oliva, Juan
    Gonzalez-Franco, Alvaro
    Cepeda, Jose Maria
    Garcia-Garcia, Jose Angel
    Gonzalez-Dominguez, Almudena
    Garcia-Casanovas, Albert
    Jimenez Merino, Silvia
    Comin-Colet, Josep
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1418 - 1424
  • [6] Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland
    Brock, Elisabeth
    Moschovitis, Giorgio
    Maeder, Micha T.
    Pfister, Otmar
    [J]. PHARMACOECONOMICS-OPEN, 2022, 6 (05) : 735 - 743
  • [7] Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland
    Elisabeth Brock
    Giorgio Moschovitis
    Micha T. Maeder
    Otmar Pfister
    [J]. PharmacoEconomics - Open, 2022, 6 : 735 - 743
  • [8] IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1695): : 22 - 24
  • [9] BUDGET-IMPACT-ANALYSIS OF IRON TREATMENT USING INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY IN AUSTRIA
    Ressl, S.
    Walter, E.
    Bauer, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A384 - A384
  • [10] Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact
    Rognoni, Carla
    Gerzeli, Simone
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (13) : 1099 - 1110
12345